Talphera Inc
Research Talphera Inc (TLPH) on Bullrun: market cap USD 63.84M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTLPH
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 63.84M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 2.56M
- Free cash flow-USD 11.29M
Valuation Snapshot
latest market cap is USD 63.84M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 28.00K | -USD 14.29M | -USD 11.36M | n/a | -0.37 | USD 5.89M | n/a | USD 17.04M |
| FY2024 | USD 0 | -USD 13.00M | -USD 12.68M | n/a | -0.51 | USD 8.86M | n/a | USD 8.00M |
| FY2023 | USD 651.00K | -USD 18.40M | -USD 17.59M | n/a | -1.29 | USD 5.72M | USD 0 | USD 14.11M |
| FY2022 | USD 0 | USD 47.76M | -USD 28.70M | n/a | 5.72 | USD 15.28M | USD 5.36M | USD 21.81M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 63.84M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 56.23M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 8.86M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 12.54M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 18.53M | 0.4 | n/a | n/a |
| 2021 | 2021-12-31 | USD 76.62M | n/a | n/a | n/a |
About Talphera Inc
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Talphera Inc's market cap?
Talphera Inc's market capitalization is USD 63.84M.
What does Talphera Inc do?
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.